Neuroblastoma recurrent
Information
- Disease name
- Neuroblastoma recurrent
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01467986 | Completed | Phase 2 | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | August 2013 | September 30, 2020 |
| NCT02139397 | Completed | Phase 1/Phase 2 | Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma | June 6, 2014 | January 19, 2024 |
| NCT02258815 | Completed | Phase 2 | CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma | August 2010 | December 2022 |
| NCT06465199 | Not yet recruiting | Phase 1/Phase 2 | Difluoromethylornithine (DFMO) and AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas | July 2024 | July 2034 |
| NCT03373097 | Recruiting | Phase 1/Phase 2 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | January 5, 2018 | December 2027 |
| NCT04239092 | Recruiting | Phase 1 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | June 5, 2020 | December 2024 |
| NCT04903899 | Recruiting | Phase 2 | 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma | May 19, 2021 | May 20, 2031 |
| NCT05754684 | Recruiting | Phase 2 | Quadruple Immunotherapy for Neuroblastoma | January 1, 2022 | December 31, 2025 |
| NCT04560166 | Terminated | Phase 2 | Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma | November 8, 2021 | September 21, 2022 |
| NCT03242603 | Unknown status | Phase 1/Phase 2 | Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells | October 3, 2017 | August 15, 2020 |